Q3 2016 13F Holders as of 9/30/2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
145
-
Total 13F shares, excl. options
-
30M
-
Shares change
-
-1.82M
-
Total reported value, excl. options
-
$2.01B
-
Value change
-
+$5.53M
-
Put/Call ratio
-
0.83
-
Number of buys
-
89
-
Number of sells
-
-56
-
Price
-
$67.05
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2016
176 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q3 2016.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 145 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30M shares
of 49.6M outstanding shares and own 60.43% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (5.69M shares), FMR LLC (4.87M shares), ORBIMED ADVISORS LLC (2.38M shares), JANUS CAPITAL MANAGEMENT LLC (2.29M shares), VANGUARD GROUP INC (2M shares), Point72 Asset Management, L.P. (1.03M shares), PRICE T ROWE ASSOCIATES INC /MD/ (931K shares), STATE STREET CORP (913K shares), WELLINGTON MANAGEMENT GROUP LLP (703K shares), and Redmile Group, LLC (662K shares).
This table shows the top 145 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.